Jena, Germany
Dynamic42 GmbH, founded in 2018 and headquartered in Germany, is carving a niche in the burgeoning field of biotech with its innovative Organ-on-Chip technology. Their mission to "develop human organ models with true physiological complexity" positions them as pioneers in in vitro disease and infection modeling. Though they operate without clearly defined industry categorization, their focus on creating sophisticated, immunocompetent organ models signifies a pioneering role in biotechnology.
Their most recent financial milestone was a Series A investment on 01 June 2023, led by bm-t Beteiligungsmanagement Thüringen. This infusion of capital underscores investor confidence in their technology and potential to revolutionize medical research and drug development. As Dynamic42 GmbH continues to expand its technological capabilities, it offers a compelling opportunity for investors seeking innovation at the intersection of biotechnology and healthcare.
